Find a Pediatric Clinical Trial

Filter By:

Title	Investigator
A Clinical Trial for Patients with Standard Risk B-Precursor Acute Lymphoblastic Leukemia [Protocol 06-039]	Shukla, Neerav, MD
A Multicenter Phase I Study of Deforolimus (AP23573) in Pediatric Patients with Advanced Solid Tumors [Protocol 08-110]	Pratilas, Christine, MD
A Multicenter Phase II Trial of ARQ197 for Patients with Relapsed or Refractory Germ Cell Tumors [Protocol 09-153]	Feldman, Darren, MD
A Non-Myeloablative Conditioning Regimen with Peri-Transplant Rituximab and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with B cell Lymphoid Malignancies [Protocol 06-066]	Barker, Juliet, MBBS
A Phase I Study of 3F8 Antibody plus Granulocyte-Macrophage Colony-Stimulating Factor in High-Risk Neuroblastoma [Protocol 05-015]	Kushner, Brian, MD
A Phase I Study of CYT 107 in Recipients of HLA-Matched T Cell-Depleted Peripheral Blood Stem Cell or Bone Marrow Transplants [Protocol 07-127]	VanDenBrink, Marcel, MD, PhD
A Phase I Study of Clofarabine Plus Topotecan, Vinorelbine, Thiotepa, and Dexamethasone in Pediatric Patients with Relapsed or Refractory Acute Leukemia [Protocol 07-012]	Steinherz, Peter, MD
A Phase I Study of Intrathecal Radioimmunotherapy Using ¹³¹I-8H9 for Central Nervous System/Leptomeningeal Cancers [Protocol 03-133]	Kramer, Kim, MD
A Phase I Study of Panitumumab in Children with Solid Tumors [Protocol 08-020]	Meyers, Paul, MD
A Phase I Study of Perifosine with Temsirolimus for Recurrent Pediatric Solid Tumors [Protocol 09-124]	Becher, Oren, MD
A Phase I Study of WT1-Sensitized T cells for Residual or Relapsed Leukemia after Allogeneic Hematopoietic Progenitor Cell Transplantation [Protocol 07-055]	O'Reilly, Richard, MD
A Phase I Study of the Monoclonal Antibody HGS-ETR2 (Lexatumumab) in Patients with Refractory Pediatric Solid Tumors [Protocol 07-071]	Chou, Alexander, MD
A Phase I Trial of a Trivalent Vaccine with Escalating Doses of the Immunological Adjuvant OPT-821 Plus Oral ß-Glucan for High-Risk Neuroblastoma [Protocol 05-075]	Kushner, Brian, MD
A Phase I/II Study of Clofarabine in Combination with Etoposide and Cyclophosphamide in Pediatric Patients with Refractory or Relapsed Acute Leukemia [Protocol 07-039]	Steinherz, Peter, MD
A Phase I/II Study of Clofarabine in Patients with Relapsed T-cell and NK-Cell Lymphomas [Protocol 06-065]	Horwitz, Steven, MD
A Phase I/II Study of the Toxic and Therapeutic Effects of T Cells in the Treatment of Epstein Barr Virus-Associated Lymphoproliferative Disorders [Protocol 95-024]	O'Reilly, Richard, MD
A Phase I/II Trial of Clofarabine, Melphalan, and Thiotepa Followed by an Allogeneic Stem Cell Transplant for the Treatment of High-Risk and/or Advanced Hematologic Malignancies [Protocol 06-125]	Boulad, Farid, MD
A Phase II Pilot Trial of Hematopoietic Stem Cell Transplantation with Total Body Irradiation, Cyclophosphamide & Fludarabine to Treat Patients with Fanconi Anemia Lacking a Genotypically Identical Donor [Protocol 01-062]	Boulad, Farid, MD
A Phase II Study of Anti-GD2 Antibody 3F8 and GM-CSF for High-Risk Neuroblastoma [Protocol 03-077]	Kushner, Brian, MD
A Phase II Study of Conformal Radiotherapy in Patients with Low-Grade Gliomas [Protocol 07-049]	Dunkel, Ira, MD
A Phase II Study of Intrathecal I¹³¹-3F8 in Patients with GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms [Protocol 05-122]	Kramer, Kim, MD
A Phase II Study of Peri-transplant Palifermin followed by an Allogeneic T-Cell-Depleted Stem Cell Transplant in Patients with Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Evolved from MDS [Protocol 08-008]	Castro-Malaspina, Hugo, MD
A Phase II Study of Radiation Therapy, Cetuximab, and Irinotecan in Children and Young Adults with Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas [Protocol 09-014]	Dunkel, Ira, MD
A Phase II Trial of HLA Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Leukemia Following Allogeneic Hematopoietic Stem Cell Transplant [Protocol 07-035]	Hsu, Katharine, MD, PhD
A Phase II Trial of Irinotecan plus Carboplatin, and Irinotecan Maintenance Therapy Integrated into the Upfront Therapy of Newly Diagnosed Patients with Intermediate- and High-Risk Rhabdomyosarcoma [Protocol 03-099]	Wexler, Leonard, MD
A Phase II Trial of Nonmyeloablative Conditioning and Transplantation of Partially HLA-Mismatched Bone Marrow for Patients with Hematologic Malignancies [Protocol 09-084]	Perales, Miguel-Angel, MD
A Phase II Trial of R1507 for People with Recurrent Sarcoma [Protocol 07-166]	Maki, Robert, MD
A Phase III Study Assessing Carboplatin and/or Isotretinoin plus Radiation in Patients with Supratentorial Primitive Neuroectodermal Tumor or High-Risk Medulloblastoma [Protocol 07-174]	Gilheeney, Stephen, MD
A Phase III Study of Gemtuzumab Ozogamicin Plus Conventional Chemotherapy in Children, Adolescents, and Young Adults with Acute Myeloid Leukemia [Protocol 09-091]	Shukla, Neerav, MD
A Phase III Study of Intensive Induction Chemotherapy with or without Methotrexate Followed by Consolidation Therapy with Stem Cell Rescue in Young Children Newly Diagnosed with Supratentorial PNET or High-Risk Medulloblastoma [Protocol 07-170]	Gilheeney, Stephen, MD
A Phase III Study of Multimodality Therapy for Extra-ocular Retinoblastoma [Protocol 08-072]	Dunkel, Ira, MD
A Pilot Phase II Study of Targeted Radiotherapy with ¹³¹I-MIBG and Arsenic Trioxide in Patients with Resistant Neuroblastoma or Malignant Chromaffin Cell Tumors [Protocol 04-148]	Modak, Shakeel, MD
A Randomized Controlled Trial of Family-Focused Grief Therapy in Palliative Care and Bereavement [Protocol 05-120]	Kissane, David, MD
A Study of Cilengitide (EMD 121974) in Recurrent or Progressive and Refractory Childhood High-Grade Glioma [Protocol 08-143]	Gilheeney, Stephen, MD
A Study of SCH 717454 in Patients with Osteosarcoma or Ewing's Sarcoma That Has Relapsed After Standard Systemic Therapy [Protocol 08-134]	Meyers, Paul, MD
A Study of Salvage Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of High-Risk or Relapsed Hodgkin's Lymphoma [Protocol 07-147]	Perales, Miguel-Angel, MD
AAML0431 for the Treatment of Young Down Syndrome Children with Acute Myeloid Leukemia and Myelodysplastic Syndrome [Protocol 09-080]	Shukla, Neerav, MD
ALTE03N1: Key Adverse Events Following Childhood Cancer [Protocol 05-070]	Sklar, Charles, MD
Adolescent and Young Adult Cancer Survivors: Identity Development [Protocol 09-001]	Ford, Jennifer, PhD
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders [Protocol 00-069]	Offit, Kenneth, MD
Carcinogen Metabolism, DNA Repair, Parental Exposures, and Retinoblastoma [Protocol 08-129]	Dunkel, Ira, MD
Classification of Acute Lymphoblastic Leukemia [Protocol 06-023]	Shukla, Neerav, MD
Combination of Targeted I¹³¹-3F8-Mediated Radioimmunotherapy and Bevacizumab in Patients with Relapsed or Refractory Neuroblastoma: A Phase I Study [Protocol 06-072]	Modak, Shakeel, MD
Cyclophosphamide, Fludarabine, and Total Body Irradiation Followed by the Transplantation of Unrelated Double-Unit Donor Umbilical Cord Blood Grafts for Patients with Hematological Malignancy [Protocol 06-014]	Barker, Juliet, MBBS
Evaluating the Causes of Cancer in Young Patients [Protocol 09-068]	Stadler, Zsofia, MD
Expanded Access of Prochymal^¿ Infusion for the Treatment of Pediatric Patients with Acute Refractory GVHD [Protocol 09-072]	Prockop, Susan, MD
Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation from HLA-Compatible Unrelated Donors in Severe Aplastic Anemia [Protocol 06-056]	Castro-Malaspina, Hugo, MD
GLIOGENE: Genetic Epidemiology of Glioma International Consortium [Protocol 07-137]	Bernstein, Jonine, PhD
Genetic Variability as a Determinant of Chemotherapy Toxicity and Response in Pediatric Cancer and Bone Marrow Transplantation Patients [Protocol 03-123]	Meyers, Paul, MD
Health-Related Outcomes for Hodgkin's Disease Survivors [Protocol 06-140]	Trippett, Tanya, MD
Hereditary Colorectal Cancer Family Registry [Protocol 01-110]	Guillem, Jose, MD
Liposomal Muramyl Tripeptide Phosphatidyl Ethanolamine (L-MTP-PE): Compassionate Access for High-Risk Osteosarcoma [Protocol 08-021]	Meyers, Paul, MD
Molecular Characterization of Neuroblastic Tumors and Clinical Outcome [Protocol 00-109]	Cheung, Nai-Kong, MD, PhD
Participation in the National Marrow Donor Program Registry [Protocol 90-091]	Kernan, Nancy, MD
Phase I Study of Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma [Protocol 09-011]	Modak, Shakeel, MD
Phase I Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors [Protocol 08-091]	Becher, Oren, MD
Phase II Prospective Clinical Trial of Vaccine Responses in Childhood Survivors of Cancer Who Had Chemotherapy [Protocol 07-088]	Small, Trudy, MD
Phase II Study of Nimotuzumab (TheraCIM^®) in Pediatric Patients with Recurrent Diffuse Intrinsic Pontine Glioma [Protocol 08-034]	Trippett, Tanya, MD
Pilot Study of Molecular Imaging Using Positron Emission Tomography (PET) to Determine Protein and Gene Expression Signatures of Colonic Polyps [Protocol 07-114]	Gollub, Marc, MD
Treatment of Atypical Teratoid/Rhabdoid Tumors of the Central Nervous System with Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation [Protocol 09-070]	Dunkel, Ira, MD
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide in Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid Rhabdomyosarcoma [Protocol 05-032]	Wexler, Leonard, MD

Site Map \| Index	Legal Disclaimer \| Privacy Practices \| Public Notices

©2010 Memorial Sloan-Kettering Cancer Center. 212-639-2000 1275 York Avenue New York, NY 10065.	PublicAffairs@mskcc.org